FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132893125> ?p ?o ?g. }

• W3132893125 endingPage "490" @default.
• W3132893125 startingPage "490" @default.
• W3132893125 abstract "Numerous cancer drugs have received accelerated approval from the US Food and Drug Administration (FDA) based on clinical trial outcomes that are otherwise not acceptable for traditional FDA approval; the accelerated approval process allows outcomes based on surrogate measures that are only reasonably likely to estimate clinical benefits. In England, the National Institute for Health and Care Excellence (NICE) evaluates the clinical benefits and cost-effectiveness of drugs after they have received regulatory approval and issues recommendations regarding their coverage in the National Health Service (NHS). However, the level of concordance between European and FDA decision-making in the context of drugs qualifying for FDA accelerated approval is unknown.To compare FDA accelerated approval decisions for cancer drugs with NICE coverage decisions.This retrospective cohort study compared cancer drug indications that received FDA accelerated approval from December 11, 1992, to May 31, 2017, with the same set of drug indication pairs in England until August 31, 2019. Data from European Public Assessment Reports developed by the European Medicines Agency (EMA) and public appraisal documents from NICE were used to determine NHS coverage recommendations. National Institute for Health and Care Excellence (NICE) public appraisal documents were analyzed for drug indications, characteristics of clinical evidence, cost-effectiveness, and coverage decisions. Data were analyzed from September 1 to December 31, 2019.Cancer drug indication coverage decision by NICE.From 1992 to 2017, 93 cancer drug indications received FDA accelerated approval, 6 of which were subsequently withdrawn, leaving 87 cancer drug indications on the market. As of August 2019, 5 of these indications had been withdrawn or denied market authorization for the European Union by the EMA. From the cohort of EMA-approved drugs, an additional 7 drug indications were not recommended by NICE and were not deemed to have sufficient clinical benefits or cost-effectiveness to warrant mandatory public coverage in England; 5 drugs were not recommended based on clinical benefit and cost-effectiveness criteria, and 2 drugs were not recommended based on cost-effectiveness criteria alone. In total, 12 drug indications were not recommended for public coverage in the NHS, and an additional 30 drug indications were not reviewed by either the EMA (14 drug indications) or NICE (16 drug indications) by the study end date. Most drug indications recommended by NICE were conditional on the negotiation of additional confidential discounts, the imposition of restricted indications that limited prescribing to specific patient subgroups, or the collection of additional data. Among the 9 drug indications with evidence of overall survival benefit at the time of NICE review, 2 were not recommended for public funding based on cost-effectiveness criteria.In this cohort study, 30 cancer drug indications that were granted accelerated approval by the FDA were not subsequently reviewed by either European regulators or NICE, and 12 drugs were denied authorization or coverage owing to insufficient safety, clinical efficacy, or cost-effectiveness. National Health Service coverage of cancer drugs given FDA accelerated approval commonly required additional price concessions, restrictions to approved indications, or review of additional data." @default.
• W3132893125 created "2021-03-01" @default.
• W3132893125 creator A5010563779 @default.
• W3132893125 creator A5022937462 @default.
• W3132893125 creator A5033279700 @default.
• W3132893125 creator A5056116418 @default.
• W3132893125 creator A5074257304 @default.
• W3132893125 date "2021-04-01" @default.
• W3132893125 modified "2023-10-13" @default.
• W3132893125 title "Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval" @default.
• W3132893125 cites W1570249624 @default.
• W3132893125 cites W1937020882 @default.
• W3132893125 cites W2010240859 @default.
• W3132893125 cites W2417870070 @default.
• W3132893125 cites W2619545114 @default.
• W3132893125 cites W2746717271 @default.
• W3132893125 cites W2754138884 @default.
• W3132893125 cites W2770583655 @default.
• W3132893125 cites W2793539832 @default.
• W3132893125 cites W2861428399 @default.
• W3132893125 cites W2908625508 @default.
• W3132893125 cites W2947583588 @default.
• W3132893125 cites W3011186552 @default.
• W3132893125 cites W4234724180 @default.
• W3132893125 cites W4242959903 @default.
• W3132893125 doi "https://doi.org/10.1001/jamainternmed.2020.8441" @default.
• W3132893125 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7900925" @default.
• W3132893125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33616607" @default.
• W3132893125 hasPublicationYear "2021" @default.
• W3132893125 type Work @default.
• W3132893125 sameAs 3132893125 @default.
• W3132893125 citedByCount "29" @default.
• W3132893125 countsByYear W31328931252021 @default.
• W3132893125 countsByYear W31328931252022 @default.
• W3132893125 countsByYear W31328931252023 @default.
• W3132893125 crossrefType "journal-article" @default.
• W3132893125 hasAuthorship W3132893125A5010563779 @default.
• W3132893125 hasAuthorship W3132893125A5022937462 @default.
• W3132893125 hasAuthorship W3132893125A5033279700 @default.
• W3132893125 hasAuthorship W3132893125A5056116418 @default.
• W3132893125 hasAuthorship W3132893125A5074257304 @default.
• W3132893125 hasBestOaLocation W31328931251 @default.
• W3132893125 hasConcept C126322002 @default.
• W3132893125 hasConcept C138816342 @default.
• W3132893125 hasConcept C142724271 @default.
• W3132893125 hasConcept C151730666 @default.
• W3132893125 hasConcept C17744445 @default.
• W3132893125 hasConcept C199360897 @default.
• W3132893125 hasConcept C199539241 @default.
• W3132893125 hasConcept C2777352838 @default.
• W3132893125 hasConcept C2779256446 @default.
• W3132893125 hasConcept C2779343474 @default.
• W3132893125 hasConcept C2780035454 @default.
• W3132893125 hasConcept C3018890749 @default.
• W3132893125 hasConcept C3020340455 @default.
• W3132893125 hasConcept C41008148 @default.
• W3132893125 hasConcept C512399662 @default.
• W3132893125 hasConcept C535046627 @default.
• W3132893125 hasConcept C71924100 @default.
• W3132893125 hasConcept C86803240 @default.
• W3132893125 hasConcept C98274493 @default.
• W3132893125 hasConcept C99454951 @default.
• W3132893125 hasConceptScore W3132893125C126322002 @default.
• W3132893125 hasConceptScore W3132893125C138816342 @default.
• W3132893125 hasConceptScore W3132893125C142724271 @default.
• W3132893125 hasConceptScore W3132893125C151730666 @default.
• W3132893125 hasConceptScore W3132893125C17744445 @default.
• W3132893125 hasConceptScore W3132893125C199360897 @default.
• W3132893125 hasConceptScore W3132893125C199539241 @default.
• W3132893125 hasConceptScore W3132893125C2777352838 @default.
• W3132893125 hasConceptScore W3132893125C2779256446 @default.
• W3132893125 hasConceptScore W3132893125C2779343474 @default.
• W3132893125 hasConceptScore W3132893125C2780035454 @default.
• W3132893125 hasConceptScore W3132893125C3018890749 @default.
• W3132893125 hasConceptScore W3132893125C3020340455 @default.
• W3132893125 hasConceptScore W3132893125C41008148 @default.
• W3132893125 hasConceptScore W3132893125C512399662 @default.
• W3132893125 hasConceptScore W3132893125C535046627 @default.
• W3132893125 hasConceptScore W3132893125C71924100 @default.
• W3132893125 hasConceptScore W3132893125C86803240 @default.
• W3132893125 hasConceptScore W3132893125C98274493 @default.
• W3132893125 hasConceptScore W3132893125C99454951 @default.
• W3132893125 hasIssue "4" @default.
• W3132893125 hasLocation W31328931251 @default.
• W3132893125 hasLocation W31328931252 @default.
• W3132893125 hasLocation W31328931253 @default.
• W3132893125 hasLocation W31328931254 @default.
• W3132893125 hasOpenAccess W3132893125 @default.
• W3132893125 hasPrimaryLocation W31328931251 @default.
• W3132893125 hasRelatedWork W1585523064 @default.
• W3132893125 hasRelatedWork W1984529021 @default.
• W3132893125 hasRelatedWork W2081124398 @default.
• W3132893125 hasRelatedWork W2134074582 @default.
• W3132893125 hasRelatedWork W2313809475 @default.
• W3132893125 hasRelatedWork W2388075619 @default.
• W3132893125 hasRelatedWork W3207854145 @default.
• W3132893125 hasRelatedWork W4230899431 @default.
• W3132893125 hasRelatedWork W4301195367 @default.

• next